← All trials
NCT04698525
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2019
- Primary completion
- Aug 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- Jan 7, 2021
- Last posted
- Jan 15, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Autonoma de San Luis PotosiLead sponsor
- Universidad Autonoma de San Luis PotosiReponsible party - principal investigator
- Universidad Autonoma de San Luis PotosiStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.